Table 3.
Treatment outcomes
| Recourse | Compassionate use program | |||
|---|---|---|---|---|
| Trifluridine/tipiracil group | All patients | Eligible patients | Ineligible patients | |
| n = 534 (%) | n = 136 (%) | n = 93 (%) | n = 43 (%) | |
| Overall responsea | 6 (1.6) | 2 (2) | 0 (0) | 2 (5) |
| Disease controla | 221 (44) | 37 (28) | 18 (20) | 19 (48) |
| Progression-free survival (months, median), 95% CI | 2.0 (1.9–2.1) | 2.1 (1.8–2.3) | 2.0 (1.9–2.2) | 2.8 (1.2–4.4) |
| Overall survival (months, median), 95% CI | 7.1 (6.5–7.8) | 5.4 (4.0–6.9) | 4.8 (3.6–6.0) | 8.2 (5.0–11.4) |
CI confidence interval
a Denominator is the number of patients evaluated for response